β-内酰胺类抗生素治疗药物监测指南
本文综述β-内酰胺类抗生素治疗药物监测(TDM)的依据与实施方法,指出%fT>MIC是预测抗菌效果的最佳药效学指标,但临床实施不足,需借助群体药代动力学软件和贝叶斯模型解读浓度,目前TDM可提高靶值达标率但临床结局获益证据有限。
要点
- β-内酰胺类TDM以%fT>MIC为药效学靶标,但临床实施常不理想。
- TDM实施需熟悉药敏试验方法,并使用群体PK软件和贝叶斯模型解读浓度。
- TDM可提高靶值达标率,但改善临床结局的证据仍有限。
核心结论
- β-内酰胺类TDM有助于实现个体化给药,但当前证据主要显示其提高靶值达标率,临床结局改善证据有限。
- 美国尚无β-内酰胺类TDM共识指南,制定指南有助于推广和标准化该实践。
研究设计与样本
- 本文为综述,讨论β-内酰胺类TDM的依据、支持证据及在特定患者群体中的实施指导。
主要发现
- β-内酰胺类%fT>MIC暴露在多种疾病状态和临床环境中常不理想。
- 实施TDM的障碍包括缺乏对如何操作和解读结果的理解,以及本地常缺乏定量设备和专业能力。
- TDM可提高靶值达标率,但改善临床结局的证据有限。
关键数值与推荐
- β-内酰胺类药效学靶标为游离浓度高于最低抑菌浓度的时间占给药间隔百分比(%fT>MIC)。
- 评估β-内酰胺类浓度最好使用群体PK软件和贝叶斯建模。
临床怎么用
- 临床实施β-内酰胺类TDM需熟悉药敏试验方法以设定浓度目标,并借助群体PK软件和贝叶斯模型解读浓度。
- 可参考外部实验室提供的β-内酰胺类TDM服务。
局限性
- 美国尚无β-内酰胺类TDM共识指南。
- TDM改善临床结局的证据有限。
- 本地常缺乏定量β-内酰胺类的设备和专业能力。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Therapeutic drug monitoring (TDM) opens the door to personalized medicine, yet it is infrequently applied to β-lactam antibiotics, one of the most commonly prescribed drug classes in the hospital setting. As we continue to understand more about β-lactam pharmacodynamics (PD) and wide inter- and intra-patient variability in pharmacokinetics (PK), the utility of TDM has become increasingly apparent. For β-lactams, the time that free concentrations remain above the minimum inhibitory concentration (MIC) as a function of the dosing interval (%fT>MIC) has been shown to best predict antibacterial effect. Many studies have shown that β-lactam %fT>MIC exposures are often suboptimal across a wide variety of disease states and clinical settings. A limitation to implementing this practice is the general lack of understanding on how to best operationalize this intervention and interpret the results. The instrumentation and expertise needed to quantify β-lactams for TDM is rarely available locally, but certain laboratories advertise these services and perform them regularly. Familiarity with the modalities and nuances of antimicrobial susceptibility testing is crucial to establishing β-lactam concentration targets that meet the relevant exposure thresholds. Evaluation of these concentrations is best accomplished using population PK software and Bayesian modeling, for which a multitude of programs are available. While TDM of β-lactams has shown an ability to increase the rate of target attainment, there is currently limited evidence to suggest that it leads to improved clinical outcomes. Although consensus guidelines for β-lactam TDM do not exist in the United States, guidance would help to promote this important practice and better standardize the approach across institutions. Herein, we discuss the basis for β-lactam TDM, review supporting evidence, and provide guidance for implementation in specific patient populations.
引用
- Fratoni AJ, Nicolau DP, Kuti JL, et al. A guide to therapeutic drug monitoring of β-lactam antibiotics. Pharmacotherapy. 2021. PMID: 33480024. doi:10.1002/phar.2505
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。